Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure.

Abstract

Duchenne muscular dystrophy (DMD) is a fatal disease of striated muscle deterioration resulting from the loss of the cytoskeletal protein dystrophin. Most patients develop significant cardiomyopathy, with heart failure being the second leading cause of death in DMD. Compared with the extensive studies on skeletal muscle defects and potential therapy in DMD… (More)

Topics

Cite this paper

@article{Townsend2007SystemicAO, title={Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure.}, author={Dewayne Townsend and Michael J Blankinship and James M. Allen and Paul Gregorevic and Jeffrey S. Chamberlain and Joseph M Metzger}, journal={Molecular therapy : the journal of the American Society of Gene Therapy}, year={2007}, volume={15 6}, pages={1086-92} }